Loading clinical trials...
Loading clinical trials...
Acetazolamide and Statins for the Treatment of Chronic Mountain Sickness in Highlanders: A Randomized Controlled Trial
This study aims to assess the effect of two drugs for the treatment of chronic mountain sickness in highlanders.
About 100 million individuals reside at high altitude (\>2500m) worldwide, with the largest populations of highlanders being found in South America (Andean), central Asia (Tibetan and Sherpa) and East Africa (Ethiopian). Despite unique adaptations to hypoxia in these populations, chronic mountain sickness (CMS) is a clinical syndrome which is observed in 5-33% of individuals residing permanently at high altitude.Several pharmacological approaches have been proposed in the treatment of EE and CMS. However, few studies show sufficient clinical evidence for safety and efficacy in CMS treatment and most highlanders with CMS remain untreated. The present project aims to better characterize chronic hypoxic responses in highlanders and to evaluate the interest of acetazolamide and statins as potential treatments for chronic mountain sickness.
Age
18 - 55 years
Sex
MALE
Healthy Volunteers
No
Association EXALT, UM Sport Pathologies, Hôpital Sud, Avenue Kimberley
Échirolles, France
Start Date
February 15, 2020
Primary Completion Date
October 30, 2021
Completion Date
December 30, 2021
Last Updated
July 31, 2025
60
ACTUAL participants
Acetazolamide
DRUG
Atorvastatin
DRUG
Placebo oral tablet
DRUG
Lead Sponsor
Centre d'Expertise sur l'Altitude EXALT
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05584813